Showing 1 - 20 results of 154 for search '"анкилозирующий спондилоартрит"', query time: 1.08s Refine Results
  1. 1
  2. 2
    Academic Journal

    Authors: Zazdravnov, A.A.

    Source: Gastroenterologìa, Vol 49, Iss 1.55, Pp 19-22 (2015)
    GASTROENTEROLOGY; № 1.55 (2015); 19-22
    Гастроэнтерология-Gastroenterologìa; № 1.55 (2015); 19-22
    Гастроентерологія-Gastroenterologìa; № 1.55 (2015); 19-22

    File Description: text/html; application/pdf

  3. 3
    Academic Journal

    Authors: Hayevska, V.Yu.

    Source: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 13, Iss 3, Pp 215-218 (2017)
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 13, № 3 (2017); 215-218
    Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 13, № 3 (2017); 215-218
    Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 13, № 3 (2017); 215-218

    File Description: application/pdf

  4. 4
    Academic Journal

    Source: Health, physical culture and sports; Vol 29 No 1 (2023): Health, Physical Culture and Sports; 49-53
    Здоровье человека, теория и методика физической культуры и спорта; Том 29 № 1 (2023): Здоровье человека, теория и методика физической культуры и спорта; 49-53

    File Description: application/pdf

  5. 5
  6. 6
  7. 7
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы заболеваний внутренних органов : Материалы конференции, посвященной 85-летию кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии (16 марта 2021 г., Уральский государственный медицинский университет, по Уральскому времени, Россия) / под ред. О. Г. Смоленской, Е. К. Бельтюкова, Т. П. Киселевой; http://elib.usma.ru/handle/usma/4848

  8. 8
  9. 9
    Academic Journal

    Source: Bulletin of Scientific Research; No. 2 (2018) ; Вестник научных исследований; № 2 (2018) ; Вісник наукових досліджень; № 2 (2018) ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2018.2

    File Description: application/pdf

  10. 10
  11. 11
  12. 12
  13. 13
    Academic Journal

    Source: Rheumatology Science and Practice; Vol 57, No 2 (2019); 222-228 ; Научно-практическая ревматология; Vol 57, No 2 (2019); 222-228 ; 1995-4492 ; 1995-4484

    File Description: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2709/1832; Насонов ЕЛ, Каратеев ДЕ. Ревматоидный артрит. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 17-57.; Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305:2525-31. doi:10.1001/jama.2011.878; Antohe J, Bili A, Sartorius JA, et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor αtherapy. Arthritis Care Res. 2012;64(2):215-21. doi:10.1002/acr.20657; Ozen G, Pedro S, Holmqvist ME, et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76:848-54. doi:10.1136/annrheumdis-2016-209954; Gupta-Ganguli M, Cox K, Means B, et al. Does therapy with antiTNF-γimprove glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011;34:e121. doi:10.2337/dc10-1334; Da Silva BS, Bonfa E, de Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010;38(5):567-9. doi:10.1016/j.biologicals.2010.05.003; Wood PR, Manning E, Baker JF, et al. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis. World J Diabetes. 2018;9(2):53-8. doi:10.4239/wjd.v9.i2.53; Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and Vascular Effects of Tumor Necrosis Factor-αBlockade with Etanercept in Obese Patients with Type 2 Diabetes. J Vasc Res. 2005;42:517-25. doi:10.1159/000088261; Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab. 2000;85:1316-9. doi:10.1210/jcem.85.3.6417; Di Rocco P, Manco M, Rosa G, et al. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res. 2004;12:734-9. doi:10.1038/oby.2004.86; Miranda-Filloy JA, Llorca J, Carnero-Lopez B, et al. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exper Rheumatol. 2012;30:850-5.; Gonzalez-Gay MA, De Matias J M, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83-6.; Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(9):1495-8. doi:10.1007/s10067-007-0539-8; Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg. 2007;62(4):218-22. doi:10.1179/acb.2007.035; Seriolo B, Ferrone C, Cutolo M. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol. 2008;35(2):355-7.; Bissell LA, Hensor EM, Kozera L, et al. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis – results from the IDEA study. Rheumatology. 2016;55(12):2181-90. doi:10.1093/rheumatology/kew306; Chen DY, Chen YM, Hsieh TY, et al. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:52. doi:10.1186/s13075-015-0559-8; Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73(1):75-85. doi:10.1136/annrheumdis-2013-203440; Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFa therapy. Scand J Rheumatol. 2007;36(2):91-6. doi:10.1080/03009740601179605; Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Antitumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R160. doi:10.1186/ar3900; Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64(5):765-6. doi:10.1136/ard.2004.026534; Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141. doi:10.1186/ar3874; Ferraz-Amaro I, Arce-Franco M, Muniz J, et al. Systemic blockade of TNF-αdoes not improve insulin resistance in humans. Horm Metab Res. 2011;43(11):801-8. doi:10.1055/s-0031-1287783; Pina T, Armesto S, Lopez-Mejias R, et al. Anti-TNF-αtherapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7):1325-30. doi:10.1111/jdv.12814; Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731-6. doi:10.1177/039463200702000408; Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007 Nov;299(9):461-5. doi:10.1007/s00403-007-0784-3; Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21(3):283-8. doi:10.1097/MEG.0b013e328325d42b; Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412-9. doi:10.1016/S0140-6736(11)60886-6; Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069-75. doi:10.2337/dc13-0604; Orban T, Beam CA, Xu P, et al. Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes. 2014;63(10):3449-57. doi:10.2337/db14-0047; Fujii M, Inoguchi T, Batchuluun B, et al. CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues. Biochem Biophys Res Commun. 2013;438(1):103-9. doi:10.1016/j.bbrc.2013.07.034; Ursini F, Russo E, Letizia Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore). 2015;94(21):e888. doi:10.1097/MD.0000000000000888; Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70(6):1164-5. doi:10.1136/ard.2010.132845; Otsuka Y, Kiyohara C, Kashiwado Y,et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi:10.1371/journal.pone.0196368; Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. doi:10.1371/journal.pone.0014328; Mirjafari H, Wang J, Klearman M, et al. Insulin resistance is improved by tocilizumab therapy in rheumatoid arthritis: results from the TOWARD study. Ann Rheum Dis. 2013;72(Suppl 3):A414-5. doi:10.1136/annrheumdis-2013-eular.1259 [Abstracts book].; Makrilakis K, Fragiadaki K, Smith J, et al. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015 Mar;34(3):419-27. doi:10.1007/s10067-014-2704-1; Tournadre A, Pereira B, Dutheil, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-46. doi:10.1002/jcsm.12189; Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014;37(2):453-9. doi:10.2337/dc13-0626; Iseri K, Iyoda M, Shikida Y, et al. Rituximab for the treatment of type B insulin resistance syndrome: a case report and review of the literature. Diabet Med. 2017;34(12):1788-91. doi:10.1111/dme.13524; Klubo-Gwiezdzinska J, Lange M, Cochran E, et al. Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study. Diabetes Care. 2018;41(11):2353-60. doi:10.2337/dc18-0884; Everett BM, Donath MY, Pradhan AD, et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018;71(21):2392-401. doi:10.1016/j.jacc.2018.03.002; Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739-48. doi:10.1161/CIRCULATIONAHA.112.122556; Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. doi:10.1056/NEJMoa065213; Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32(9):1663-8. doi:10.2337/dc09-0533; Van Poppel PC, van Asseldonk EJ, Holst JJ, et al. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16(12):1269-73. doi:10.1111/dom.12357; Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905-15. doi:10.1016/S0140-6736(13)60023-9; Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators. Effect of anti-IL-1βantibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14(12):1088-96. doi:10.1111/j.1463-1326.2012.01637.x; Van Asseldonk EJ, van Poppel PC, Ballak DB, et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol. 2015;160(2):155-62. doi:10.1016/j.clim.2015.06.003

  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    Academic Journal

    Source: Relevant lines of scientific research: development prospects; № 2; 42-44 ; Актуальные направления научных исследований: перспективы развития; № 2; 42-44

    File Description: text/html

    Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-9500562-3-9; https://interactive-plus.ru/e-articles/418/Action418-463198.pdf; 1. Насонов Е.Л. Проблемы остеопороза в ревматологии / Под ред. Е.Л. Насонова, И.А. Скрипниковой, В.А. Насоновой. – М., 1997, – 357 c.; 2. Bessant R. How should clinicians manage osteoporosis in ankylosing spondylitis? / R. Bessant, A. Keat // The Journal of Rheumatology. – 2002. – 29 (7). – P. 1511–1519.; 3. Maghraoui A. Osteoporosis and ankylosing spondylitis / A. Maghraoui // Joint Bone Spine. – 2004. – 7 (4). – P. 291–295.; 4. Mitra D. The prevalence of vertebral compression fractures in mild ankylosing spondylitis and their relationship to bone mineral density / D. Mitra, D.M. Elvins, D.J. Spenden [et al.] // Rheumatology (Oxford). – 2000. – №39. – P. 85–89.; 5. Reveille J.D. Spondyloarthritis; update on pathogenesis and management / J.D. Reveille, F.C. Arnett // The American Journal of Medicine. – 2005. – 118 (6). – P. 592–603.

  20. 20